Lenalidomide: an update on evidence from clinical trialsDIMOPOULOS, Meletios-Athanassios; TERPOS, Evangelos.Blood reviews. 2010, Vol 24, Num SUP1, issn 0268-960X, S21-S26Article

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosisSANCHORAWALA, Vaishali; FINN, Kathleen T; FENNESSEY, Salli et al.Blood. 2010, Vol 116, Num 11, pp 1990-1991, issn 0006-4971, 2 p.Article

Lenalidomide mode of action: linking bench and clinical findingsDAVIES, Faith; BAZ, Rachid.Blood reviews. 2010, Vol 24, Num SUP1, issn 0268-960X, S13-S19Article

Lenalidomide and thalidomide : Mechanisms of action-similarities and differencesANDERSON, Kenneth C.Seminars in hematology. 2005, Vol 42, Num 4, pp S3-S8, issn 0037-1963, SUP4Article

Lenalidomide : Patient management strategiesHUSSEIN, Mohamad A.Seminars in hematology. 2005, Vol 42, Num 4, pp S22-S25, issn 0037-1963, SUP4Article

Treatment of Refractory Prurigo Nodularis With LenalidomideKANAVY, Holly; BAHNER, Jennifer; KORMAN, Neil J et al.Archives of dermatology (1960). 2012, Vol 148, Num 7, pp 794-796, issn 0003-987X, 3 p.Article

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosisTAPAN, Umit; SELDIN, David C; FINN, Kathleen T et al.Blood. 2010, Vol 116, Num 23, pp 5071-5072, issn 0006-4971, 2 p.Article

Efficacy of lenalidomide in myelodysplastic syndromesLIST, Alan; KURTIN, Sandy; ROE, Denise J et al.The New England journal of medicine. 2005, Vol 352, Num 6, pp 549-557, issn 0028-4793, 9 p.Article

Drug reaction with eosinophilia and systemic symptoms caused by lenalidomideFOTI, Caterina; ANTELMI, Annarita; MAZZOCCA, Antonio et al.EJD. European journal of dermatology. 2012, Vol 22, Num 6, pp 799-800, issn 1167-1122, 2 p.Article

Lenalidomide for Treatment of Myelodysplastic Syndromes: Current Status and Future DirectionsKOMROKJI, Rami S; LIST, Alan F.Hematology/oncology clinics of North America. 2010, Vol 24, Num 2, issn 0889-8588, viii-ix, 377-388 [13 p.]Article

Utilisation du lénalidomide dans les syndromes myélodysplasiques del(5q)ADES, L.Correspondances en onco-hématologie. 2014, Vol 9, Num 2, pp 76-80, issn 1954-4820, 5 p.Article

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesisNARLA, Anupama; DUTT, Shilpee; MCAULEY, J. Randall et al.Blood. 2011, Vol 118, Num 8, pp 2296-2304, issn 0006-4971, 9 p.Article

Remitting activity of lenalidomide in treatment-induced myelodysplastic syndromeMELCHERT, M; WILLIAMS, C; LIST, A et al.Leukemia. 2007, Vol 21, Num 7, pp 1576-1578, issn 0887-6924, 3 p.Article

Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesSINHA, S; GERTZ, M. A; RAJKUMAR, S. V et al.Leukemia. 2012, Vol 26, Num 5, pp 1119-1122, issn 0887-6924, 4 p.Article

Role of Lenalidomide in the Treatment of Myelodysplastic SyndromesKOMROKJI, Rami S; LIST, Alan F.Seminars in oncology. 2011, Vol 38, Num 5, pp 648-657, issn 0093-7754, 10 p.Article

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13FEHNIGER, Todd A; BYRD, John C; MARCUCCI, Guido et al.Blood. 2009, Vol 113, Num 5, pp 1002-1005, issn 0006-4971, 4 p.Article

Dose Escalation of Lenalidomide in Relapsed or Refractory Acute LeukemiasBLUM, William; KLISOVIC, Rebecca B; CURFMAN, John et al.Journal of clinical oncology. 2010, Vol 28, Num 33, pp 4919-4925, issn 0732-183X, 7 p.Article

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasiasZAGOURI, Flora; ROUSSOU, Maria; DIMOPOULOS, Meletios-Athanasios et al.American journal of hematology. 2011, Vol 86, Num 10, pp 882-884, issn 0361-8609, 3 p.Article

Lenalidomide and dexamethasone in the treatment of AL amyloidosis : results of a phase 2 trial. CommentarySCHECHTER, Geraldine P; SANCHORAWALA, Vaishali; WRIGHT, Daniel G et al.Blood. 2007, Vol 109, Num 2, issn 0006-4971, 391-392,492-496 [7 p.]Article

Lenalidomide in solid tumorsSEGLER, Angela; TSIMBERIDOU, Apostolia-Maria.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 6, pp 1393-1406, issn 0344-5704, 14 p.Article

Pharmacokinetics, metabolism and excretion of [¹⁴C]-lenalidomide following oral administration in healthy male subjectsNIANHANG CHEN; LIAN WEN; LAU, Henry et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 3, pp 789-797, issn 0344-5704, 9 p.Article

Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primatesMUSCAL, Jodi A; SUN, Yongkai; NUCHTERN, Jed G et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 943-947, issn 0344-5704, 5 p.Article

Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumorsOECHSLE, Karin; BOKEMEYER, Carsten; HONECKER, Friedemann et al.Journal of cancer research and clinical oncology. 2010, Vol 136, Num 1, pp 165-167, issn 0171-5216, 3 p.Article

The Heterogeneous Prognosis of Patients With Myelodysplastic Syndrome and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?KANTARJIAN, Hagop; O'BRIEN, Susan; GARCIA-MANERO, Guillermo et al.Cancer. 2009, Vol 115, Num 22, pp 5202-5209, issn 0008-543X, 8 p.Article

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletionXIMERI, Maria; GALANOPOULOS, Athanasios; HATZIMICHAEL, Eleftheria et al.Haematologica (Roma). 2010, Vol 95, Num 3, pp 406-414, issn 0390-6078, 9 p.Article